AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Aprea Therapeutics, Inc. Common stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Q6Q3KV6
0.52▼ 0.02 (-4.41%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.54
Day's Range
0.50 – 0.55
52-Week Range
0.50 – 1.57
Volume
84.1K
Avg Volume
221.1K
Share Statistics
Shares Outstanding
Employees
8
Exchange
XNAS
Listed
2019-10-03
Share count as of August 12, 2026

Aprea Therapeutics, Inc. Common stock (APRE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Aprea Therapeutics, Inc. Common stock (APRE)
What is Aprea Therapeutics, Inc. Common stock's Market Cap?
Aprea Therapeutics, Inc. Common stock's Market Cap is $6.5M, based on as-reported figures from SEC (XBRL) filings.
What is Aprea Therapeutics, Inc. Common stock's Enterprise Value?
Aprea Therapeutics, Inc. Common stock's Enterprise Value is -$34.7M, based on as-reported figures from SEC (XBRL) filings.
What is Aprea Therapeutics, Inc. Common stock's EV / EBITDA?
Aprea Therapeutics, Inc. Common stock's EV / EBITDA is 2.6×, based on as-reported figures from SEC (XBRL) filings.
What is Aprea Therapeutics, Inc. Common stock's Net Income (TTM)?
Aprea Therapeutics, Inc. Common stock's Net Income (TTM) is -$12.3M, based on as-reported figures from SEC (XBRL) filings.
What is Aprea Therapeutics, Inc. Common stock's EBITDA?
Aprea Therapeutics, Inc. Common stock's EBITDA is -$13.2M, based on as-reported figures from SEC (XBRL) filings.
What is Aprea Therapeutics, Inc. Common stock's Diluted EPS (TTM)?
Aprea Therapeutics, Inc. Common stock's Diluted EPS (TTM) is -0.98, based on as-reported figures from SEC (XBRL) filings.
What is Aprea Therapeutics, Inc. Common stock's Net Debt?
Aprea Therapeutics, Inc. Common stock's Net Debt is -$41.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · APREAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss
Grant revenue——
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Other income———
Foreign currency gain (loss)
Total other income
Net loss
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)